Three dimensional conformal radiation therapy (3DCRT) for prostate cancer is most commonly delivered with high-energy photons, typically in the range of 10-21 MV. With the advent of Intensity Modulated Radiation Therapy (IMRT), an increase in the number of monitor units (MU) relative to 3DCRT has lead to a concern about secondary malignancies. This risk becomes more relevant at higher photon energies where there is a greater neutron contribution. Subsequently, the majority of IMRT prostate treatments being delivered today are with 6-10 MV photons where neutron production is negligible. However, the absolute risk is small [Hall, E. J. Intensity Modulated Radiation Therapy, Protons, and the Risk of Second Cancers. Int J Radiat Oncol Bio Phys 65, 1-7 (2006); Kry, F. S., Salehpour, M., Followill, D. S., Stovall, M., Kuban, D. A., White, R. A., and Rosen, I. I. The Calculated Risk of Fatal Secondary Malignancies From Intensity Modulated Radiation Therapy. Int J Radiat
Introduction
Three-dimensional conformal radiation therapy (3DCRT) for prostate cancer is most commonly delivered with high-energy photons, typically in the range of 10-21 MV due to the greater penetration of dose with depth (3). With the advent of Intensity Modulated Radiation Therapy (IMRT), an increase in the number of monitor units (MU) relative to 3DCRT has lead to a concern about the patients' total body neutron burden incurred during treatment with these high energy photon beams. Consequently, the majority of IMRT prostate treatments delivered today are with lower energy (6-10 MV) photons where neutron production in a linear accelerator treatment head is negligible (4). Another investigation (5) demonstrated that target dose conformity may be similar for a range of megavoltage photon energies for deep-seated tumors while dose in regions far from the target may receive higher doses for lower energies.
In this work, the effect of beam energy on the quality of IMRT plans for prostate conformal radiotherapy is systematically studied for competing IMRT plans optimized for delivery with either 6 or 18 MV beams. To ensure that differences among plans are due only to energy selection, the beam arrangement, number of beams, and dose constraints were kept constant for all plans. Quality indicators include a comparison of dose conformity to the target volumes along with total integral doses (photon and neutron) to three different tissue volumes.
Materials and Methods
In our practice, intermediate risk prostate cancer patients are typically treated with a comprehensive course of radiation therapy including 3DCRT for the initial 45 Gy (delivered with 18 MV) followed by an IMRT boost for an additional 36 Gy. The IMRT portion of the treatment is delivered to the PTV (Planning target volume) using five coplanar 6 MV fields at gantry angles of 255, 315, 45, 105, and 180 degrees. The treatment machine is an isocentric linear accelerator (Clinac 2100 C/D, Varian Associates, Palo Alto, CA) incorporating a 52-leaf MLC (Mark Series, Varian Associates, Palo Alto, CA). The location of the PTV relative to linac isocenter is verified daily with ultrasound guidance (BAT, Nomos Corporation, Sewickley, PA).
A competing IMRT plan with the same beam geometry, contouring, and dose constraints as the clinically delivered plan was developed using 18 MV beams for 10 patients recently treated at our facility for prostate cancer (stage 2 disease). All IMRT plans were calculated using an inverse treatment planning algorithm (Eclipse Helios v 7.1.59, Varian Medical Systems, Palo Alto, CA) with the dose calculation grid set at 2 mm. The ten patient image sets were chosen to eliminate extreme anatomy conditions (e.g., very small bladder). For each patient's initial plan, the gross tumor volume (GTV) was defined as the prostate and seminal vesicles and then re-duced to just the prostate for the IMRT boost. The planning target volume (PTV) was created by expanding the GTV by 1 cm in all directions, except posteriorly for the IMRT plan, where a 0.6 cm margin was used. Two rectal contours were defined. The first included all imaged rectal tissue, while the second (Rectum_IMRT) included only rectal tissue extending 3 mm superiorly and 3 mm inferiorly from the PTV (see Figure 1 ). This definition of Rectum_IMRT was choosen as it was more sensitive to the optimization of co-planar field plans. This makes the comparison of rectal doses among different patients more sensitive to the quality of the plan and less dependent on to the anatomy of the patient. All patients were imaged with full bladders, which were also contoured. A summary of the volumes of each individual patient's contoured anatomies is given in Table I. For dose optimization, the following dose constraints were defined for the PTV: a minimum of 36 Gy to 100% of the volume (priority of 105) with a maximum dose of 38.2 Gy (priority of 70). The dose-volume constraints for normal tissues are listed in Table II . Dose constraints were set slightly lower than generally achievable to ensure each plan did not satisfy the constraints yet not be the optimal plan. The constraints chosen are consistent with the normal tissue tolerance data published by the Radiation Therapy Oncology Group (6) and were deemed achievable based on our experience. Neutron dose calculations were made using the method suggested by McCall (7, 8) . The neutron contamination fluence in the environment surrounding a linac similar to the one in our facility is documented in the literature (9). For 18 MV photon beams, the in-field fluences were reported to be 109 and 121 × 10 3 cm -2 /MU for external beam and IMRT, respectively, while out of field fluence values are 75 and 93 × 10 3 cm -2 /MU, respectively. The higher neutron fluence for IMRT delivery is presumably the result of more direct photon interaction with an MLC during IMRT. Dose equivalents per MU were then calculated using specific patient physical parameters. These dose equivlalents were then converted to total neutron dose through scaling of the entire prescription dose.
Comparison of the plans created by different energies will be performed by evaluating the following parameters: (a) entrance and exit dose, (b) dose volume histograms, (c) conformity index, (d) photon integral dose, and (e) neutron integral dose.
Results and Discussion
A quantitative comparison of DVHs between different plans is most meaningful when similar target doses are achieved. This was accomplished by normalizing the plans to have equal dose of 37.8 Gy (105% of prescription) at the 50% volume point of each PTV's DVH. This point typically represents the steepest part of the PTV dose-volume histogram and normalizing this way makes the target DVHs for all plans very similar. A mean DVH for each anatomy and energy was then determined by averaging the volumes in each dose bin and re-plotting the resulting data as a function of dose. In analyzing the mean DVHs, it was found that the prescription dose (36 Gy) was delivered to 94% and 95% of the PTV volumes for 6 MV and 18 MV, respectively, well within the limits for a clinically acceptable plan. Comparison of (a) entrance and exit dose, (b) dose volume histograms, (c) conformity index, (d) photon integral dose, and (e) neutron integral dose will now be discussed.
Entrance and Exit Dose
Figures 2(a-c) show the resulting dose distribution from a subtraction of the 18 MV dose matrix from the 6 MV dose matrix for one patient. This data is representative of the results for all patients in this study. Transverse, sagittal, and coronal views are shown. A continuous scale is used to represent the dose difference, with red indicating up to 2 Gy of extra dose in the 6 MV plan, and blue indicating up to 1 Gy extra dose in the 18 MV plan. Green and purple indicate little difference between plans. As expected, the periphery of each view tends to be red in the entrance region of each beam, showing a higher entrance dose with 6 MV. Similarly, the blue regions in the periphery show greater exit dose with 18 MV. The PTV region is mostly green, indicating little difference between plans. This is to be expected since the plans were optimized with identical dose-volume constraints for the PTV. 
Dose Volume Histograms
The mean DVH for the following structures was calculated for all plans using the methodology described above: body, bladder, prostate, PTV, rectum_IMRT, and rectum. Mean DVHs for all anatomies and both 6 MV and 18 MV beam energies are shown in Figure 3 . The mean DVH for the body demonstrates that the 6 MV plan has a slightly higher volume receiving photon dose up to 2 Gy. This can be explained by the fact that 6 MV plans require a higher number of MU (see below), resulting in greater MLC transmission dose outside the target region. Between 2 and 6 Gy, more volume is irradiated for the 18 MV plan, reflective of the higher exit dose for treatment with 18 MV. However, be-tween 6 and 20 Gy, more volume is irradiated for the 6 MV plan, again resulting from a higher entrance dose for the 6 MV plan. And finally, after 20 Gy, mean body DVHs for both energies are indistinguishable.
For the bladder in the 0 to 2 Gy region, the 6 MV plan irradiates greater volume, again a result of more MLC transmission with the greater number of MU in 6 MV plans. For the prostate target, the 6 MV mean DVH is found to be slightly steeper than that for 18 MV. As expected, the PTV coverage with both energies is not significantly different because identical constraints were used in the optimization and, as mentioned above, the plans were subsequently normalized to have the same PTV dose. For both Rectum_IMRT and rectum between the region of 10 Gy and 16 Gy, 6 MV has higher integral photon dose because the rectum as a structure is closer to the surface and the peripheral dose, as shown in Figure 2 , is higher for 6 MV.
Conformity Index
In this work, the conformity index is defined as the ratio of the volume of the body receiving the prescription dose to the volume of the PTV receiving the same dose. Table III shows the conformity index for all ten patients and both beam energies. The mean conformity index was 1.05 (range of 1.02 to 1.09) and 1.06 (1.03 to 1.10) for 6 MV and 18 MV, respectively. These small differences indicate that the plans are nearly identical in their conformity of dose to the target.
Integral Dose
Table IV summarizes the photon integral dose for all ten patients and both beam energies. Since the IMRT fields are arranged so that the beams do not oppose, the integral dose ratio is somewhat predictable according to Figure 4 . Traditionally, 18 MV photons are preferred for conformal pelvic irradiations because for targets deeper than about a third of the patient separation, the maximum dose as well as the integral dose will be lower as compared to a plan with only 6 MV photons. Figure 4 shows the points where integral dose is equal for single 6 and 18 MV beams. This presents different rationale for using 6 MV or 18 MV photons for IMRT prostate treatment. In evaluation of energy selection, comparison of target coverage, critical structure dose, photon integral dose, conformity index, and neutron integral dose were analyzed. For the patient population in this study, the average depth to isocenter is 10.5 cm and the average separation is 32 cm. The point corresponding to this data lies slightly below the iso-integral dose line in Figure 4 , implying that the photon integral dose for 6 MV will be slightly higher than for 18 MV. The data in Table IV supports this predic- tion. The average integral dose for 6 MV plans is 9% higher (range of 7-10%) than for the 18 MV plans. A thorough comparison of integral dose must include dose contribution from neutrons produced via photodisintegration mainly within the linac treatment head. It is well known that 18 MV photons will activate materials causing neutron release, where 6 MV photons are below the threshold for neutron production.
Neutron Dose
Neutron integral doses were calculated throughout three separate volumes: pelvic region directly receiving primary radiation (Table V) , entire pelvic region image set (Table VI) , and the total body (Table VII) . . This is expected due to the higher penetrability of the 18 MV photons. The number of monitor units for the 18 MV plans will be required for neutron dose calculations. For comparison purposes, two non-IMRT four-field box, external plans, one with 18 MV photons, and the other with 6 MV photons, were generated for one image set.
The photon and neutron integral dose calculated throughout the pelvic region directly irradiated by the co-planar beams is summarized in Table V . The volume of tissue analyzed is that which receives greater than 5% of the prescription dose. This closely corresponds to a volume of all slices that receive primary irradiation. Conversions of volume to mass in Tables V-VII are done assuming the tissue is water equivalent (density of 1 g/cm 3 ). The neutron dose is calculated using an in field dose of 24.2 μSv / MU (9). The mean fractional neutron integral dose within this volume for 20 fraction of 1.8 Gy is found to be 1.5 J (range 1.3 to 2.1 J).
The total integral dose can be determined by summing this neutron dose with the 18 MV photon dose calculated from the treatment planning system. On average, the photon integral dose was 47.6 J and the neutron dose was 1.5 J, yielding a total average dose for this volume of 49.1 J. The 6 MV IMRT plan yields a total integral dose of 51.1 J for this same volume, which is 1.04 times greater than the 18 MV total integral dose. The dose values for the 4 field static external plan were calculated using neutron dose values of 21.8 μSv/MU (9) in field and 15.0 μSv/MU (9) out of field. The fewer monitor units and smaller neutron dose per MU result in significantly lower total neutron dose for non-IMRT plans as shown in the last row of Tables V, VI, and VII.
This analysis was repeated for the full pelvic volume that was acquired in the CT image set. The neutron dose calculation was then performed using an in field neutron dose of 24.2 μSv/MU and out field neutron dose of 18.6 μSv/MU (9). This increased volume increases the tissue receiving scatter dose and the tissue receiving out of field neutron dose. The total integral dose for this volume is 60.5 J and 62 J for 18 MV and 6 MV, respectively. This increase in neutron integral dose reduces the ratio of 6 MV integral dose to 18 MV integral dose to 1.03.
The neutrons produced in the accelerator head contribute dose to the entire patient's body. Neutron dose contribution from a Varian 2100 CD outside of the primary field for 18 MV photons is reported to be 15 μSv/MU for static beam and 18.6 μSv/MU for IMRT beams (9). The neutron dose contribution was calculated based on the mass of each patient and the known number of MU by using the McCall method (7, 8) . In addition to this neutron dose, photon dose due to leakage must be accounted for. A leakage value of 0.1% of the isocenter dose was used for both energies (10). This photon dose is integrated over the entire mass of the patient and contributes 14.6% of the total dose to the 6 MV IMRT plans and 10.2% for the 18 MV plan. The average contribution from total body neutron dose is nearly double (18.4 J/9.9 J = 1.86) the photon leakage dose for 18 MV photons. Incorporating both the total body neutron dose and total body photon dose will significantly lower the total integral dose ratio of 6 MV IMRT plans to 18 MV IMRT plans to 0.875 as summarized in Table VII .
Conclusion
The tradeoff of using 6 or 18 MV for prostate patients depends on many parameters. Since we forced the same PTV coverage for both energies by having the same optimization constraints, there was little difference in target coverage and conformity index for both energies.
DVHs for the critical structures showed little difference between 6 MV IMRT and 18 MV IMRT plans. There was a slight increase of 2.5% of the rectal volume receiving 33% of the dose when averaged for the ten patients. This is due to the higher entrance dose with 6 MV photons from the posterior beam. The 6 MV IMRT photon integral dose is 9% higher than the 18 MV IMRT plan. When neutron dose is considered the ratio of 6 MV to 18 MV integral dose decreases to 1.04 in the treatment volume and 0.84 when the entire body is considered.
These results indicate that there is no clinical benefit with respect to target coverage and normal tissue sparing when comparing 18MV IMRT versus 6 MV IMRT. It also demonstrates that the ability to generate acceptable IMRT plans is independent of the energies in the 6-18 MV range. The higher total body dose in 18 MV IMRT plans should be considered by the clinician when choosing the optimal treatment course for a patient.
